Abstract Number: 2542 • 2017 ACR/ARHP Annual Meeting
Measuring Psoriasis Specific Impact on Quality of Life: Performance of Dlqi and Skindex-17 in Early Psoriatic Arthritis
Background/Purpose: Impact of dermatological disease is measured with the Dermatology Life Quality Index (DLQI) and Skindex-17. DLQI is commonly used in dermatology trials but the…Abstract Number: 2543 • 2017 ACR/ARHP Annual Meeting
Agreement between Paper and Pencil VAS at the Clinic and Electronic VAS at Home in Psoriatic Arthritis and Its Impact on Minimal Disease Activity
Background/Purpose: Presence of Minimal Disease Activity (MDA) in Psoriatic Arthritis (PsA) is determined using a patient Visual Analogue Scale (VAS) global PsA activity and VAS…Abstract Number: 2544 • 2017 ACR/ARHP Annual Meeting
Psoriatic Arthritis Impact of Disease (PSAID12) in Early Psoriatic Arthritis: Pain As One of the Main Determinants of Disease Impact
Background/Purpose: The Psoriatic Arthritis Impact of Disease 12-item questionnaire (PsAID12) has been developed to measure impact of Psoriatic Arthritis (PsA) for purposes of monitoring and…Abstract Number: 2545 • 2017 ACR/ARHP Annual Meeting
Can Achieving Sustained Minimal Disease Activity (MDA) Prevent Progression of Subclinical Atherosclerosis? a Two-Year Prospective Cohort Study in Psoriatic Arthritis
Background/Purpose: PsA patients have higher cardiovascular disease risk due to underlying inflammation. While achieving MDA was associated with articular benefits, its effect on CVD risk…Abstract Number: 2546 • 2017 ACR/ARHP Annual Meeting
Secukinumab Decreases Arterial Wall Inflammation in Patients with Peripheral Spondyloarthritis
Background/Purpose: Patients with spondyloarthritis (SpA), a chronic inflammatory disease, have an increased cardiovascular risk, which is partly due to increased inflammatory activity in the arterial…Abstract Number: 2547 • 2017 ACR/ARHP Annual Meeting
the Ideal Target for Psoriatic Arthritis? Comparison of Remission and Low Disease Activity States in a Real Life Cohort
Background/Purpose: Recommendations on psoriatic arthritis (PsA) state that the target of treatment should be remission or inactive disease with an alternative target of minimal or…Abstract Number: 2548 • 2017 ACR/ARHP Annual Meeting
Validation of New Potential Targets for Remission and Low Disease Activity in Psoriatic Arthritis in Patients Treated with Golimumab
Background/Purpose: Treat to target recommendations in PsA state that the target of treatment should be remission or low disease activity (LDA). So far, the only…Abstract Number: 2549 • 2017 ACR/ARHP Annual Meeting
Achievement of Minimal Disease Activity Is Associated with Improvements in Health-Related Quality of Life and Productivity in Psoriatic Arthritis Patients
Background/Purpose: Treatment goals in psoriatic arthritis (PsA) are moving toward attainment of absolute therapeutic thresholds rather than relative improvement. Minimal disease activity (MDA), a composite…Abstract Number: 2550 • 2017 ACR/ARHP Annual Meeting
A New and Simpler Tool for Global Psoriatic Arthritis Assessment: Simplified Composite Psoriatic Disease Activity Index (sCPDAI)
Background/Purpose: The heterogeneity of psoriatic arthritis ( PsA) that includes a possible combination of axial disease, peripheral arthritis, enthesitis, dactylitis, skin and nail involvement, makes…Abstract Number: 2551 • 2017 ACR/ARHP Annual Meeting
Comparison between Two Cut-Off Values of Disease Activity in Psoriatic Arthritis Index and Validation of Its Simplified Clinical Version in Patients with Psoriatic Arthritis
Background/Purpose: Two groups established cut-off values for Disease Activity Index for Psoriatic Arthritis (DAPSA)1-2. The clinical DAPSA (cDAPSA) excludes CRP from its calculation and the…Abstract Number: 2552 • 2017 ACR/ARHP Annual Meeting
Inter-Connections between Fatigue, Pain and Patient Global Assessement in Patients with Active Spondyloarthritis Followed in the Daily Clinic
Background/Purpose: The Assessment of SpondyloArthritis international Society (ASAS) has selected fatigue, pain and patient global assessment (PaGl) as key patient-reported outcome measures in clinical trials…Abstract Number: 2553 • 2017 ACR/ARHP Annual Meeting
Patient and Physician Global Assessment Are Poorly Inter-Connected and Poorly Explained By Other Clinical Markers of Disease Activity in Individual Patients with Psoriatic Arthritis
Background/Purpose: Assessment of disease activity is important in the evaluation and monitoring of patients with psoriatic arthritis (PsA) in clinical care and research. As there…Abstract Number: 2554 • 2017 ACR/ARHP Annual Meeting
Disease Activity in Psoriatic Arthritis-ESR Index Maybe a Valid Tool to Evaluate Disease Activity in Patients with Psoriatic Arthritis When CRP Is Not Available
Background/Purpose: DAPSA is a composite index to assess disease activity in patients with Psoriatic Arthritis (PsA) which includes joint count 66/68, pain and patient´s global…Abstract Number: 2555 • 2017 ACR/ARHP Annual Meeting
Clinical History of Psoriatic Arthritis over Four Decades
Background/Purpose: Psoriatic arthritis (PsA) is an inflammatory musculoskeletal disease associated with psoriasis. Over the past several decades it was recognized that PsA is more common…Abstract Number: 2556 • 2017 ACR/ARHP Annual Meeting
Were Moll and Wright Right?
Background/Purpose: In 1973 Moll and Wright published the first paper on the classification criteria for Psoriatic Arthritis (PsA). In their pioneering work, these authors additionally…
ACR Meeting Abstracts